BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

920 related articles for article (PubMed ID: 18609117)

  • 21. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme.
    Rossner S; Lange-Dohna C; Zeitschel U; Perez-Polo JR
    J Neurochem; 2005 Jan; 92(2):226-34. PubMed ID: 15663471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Presenilin 1 is involved in the maturation of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1).
    Kuzuya A; Uemura K; Kitagawa N; Aoyagi N; Kihara T; Ninomiya H; Ishiura S; Takahashi R; Shimohama S
    J Neurosci Res; 2007 Jan; 85(1):153-65. PubMed ID: 17075903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.
    Portelius E; Brinkmalm G; Tran AJ; Zetterberg H; Westman-Brinkmalm A; Blennow K
    Neurodegener Dis; 2009; 6(3):87-94. PubMed ID: 19229112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association study between Alzheimer's disease and genes involved in Abeta biosynthesis, aggregation and degradation: suggestive results with BACE1.
    Clarimón J; Bertranpetit J; Calafell F; Boada M; Tàrraga L; Comas D
    J Neurol; 2003 Aug; 250(8):956-61. PubMed ID: 12928915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's disease.
    Johnston JA; Liu WW; Todd SA; Coulson DT; Murphy S; Irvine GB; Passmore AP
    Biochem Soc Trans; 2005 Nov; 33(Pt 5):1096-100. PubMed ID: 16246054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain.
    Stockley JH; Ravid R; O'Neill C
    FEBS Lett; 2006 Dec; 580(28-29):6550-60. PubMed ID: 17113083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
    Ohno M; Chang L; Tseng W; Oakley H; Citron M; Klein WL; Vassar R; Disterhoft JF
    Eur J Neurosci; 2006 Jan; 23(1):251-60. PubMed ID: 16420434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of peptides derived from BACE1 catalytic domain on APP processing.
    Yeon SW; Jeon YJ; Hwang EM; Kim TY
    Peptides; 2007 Apr; 28(4):838-44. PubMed ID: 17293005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice.
    Asai M; Hattori C; Iwata N; Saido TC; Sasagawa N; Szabó B; Hashimoto Y; Maruyama K; Tanuma S; Kiso Y; Ishiura S
    J Neurochem; 2006 Jan; 96(2):533-40. PubMed ID: 16336629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measuring APP carboxy-terminal fragments.
    Esposito LA
    Methods Mol Biol; 2011; 670():71-84. PubMed ID: 20967584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease.
    Ewers M; Cheng X; Zhong Z; Nural HF; Walsh C; Meindl T; Teipel SJ; Buerger K; He P; Shen Y; Hampel H
    J Alzheimers Dis; 2011; 25(2):373-81. PubMed ID: 21460439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amyloid beta and APP as biomarkers for Alzheimer's disease.
    Zetterberg H; Blennow K; Hanse E
    Exp Gerontol; 2010 Jan; 45(1):23-9. PubMed ID: 19698775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of amyloid beta-peptide production by blockage of beta-secretase cleavage site of amyloid precursor protein.
    Na CH; Jeon SH; Zhang G; Olson GL; Chae CB
    J Neurochem; 2007 Jun; 101(6):1583-95. PubMed ID: 17542811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
    Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
    J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lactacystin decreases amyloid-beta peptide production by inhibiting beta-secretase activity.
    Kienlen-Campard P; Feyt C; Huysseune S; de Diesbach P; N'Kuli F; Courtoy PJ; Octave JN
    J Neurosci Res; 2006 Nov; 84(6):1311-22. PubMed ID: 16941495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
    Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
    Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
    Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measurement of cellular beta-site of APP cleaving enzyme 1 activity and its modulation in neuronal assay systems.
    Volbracht C; Penzkofer S; Mansson D; Christensen KV; Fog K; Schildknecht S; Leist M; Nielsen J
    Anal Biochem; 2009 Apr; 387(2):208-20. PubMed ID: 19454261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.